Cryoport Systems Redefines the Global Supply Chain with Launch of New Facility Near Paris, France

As a leader in temperature-controlled life sciences supply chain solutions, Cryoport Systems is thrilled to announce the grand opening of our revolutionary Global Supply Chain Center in Louvres, France. Strategically positioned just minutes from Paris’ Charles de Gaulle Airport, this state-of-the-art, 55,000-square-foot facility is set to transform the way advanced therapies are delivered globally, cementing our position as the go-to partner for biopharma innovation.

This cutting-edge campus is a one-stop location for end-to-end, temperature-controlled supply chain solutions and is designed to tackle the most complex challenges in the life sciences industry. As the third addition to Cryoport System’s Global Supply Chain Center (GSCC)  network, the Louvres facility delivers unmatched accessibility for biologics and temperature-sensitive materials, ensuring life-changing therapies reach patients faster and more reliably than ever before.

 

Ready to Revolutionize from Day One

The Louvres center hits the ground running, offering immediate logistics support for cell therapy, gene therapy, biologics, animal health, and reproductive medicine. To expand into a true end-to-end solution, in the coming months we will roll out an expanded suite of services, including bioservices and biostorage, to support both clinical and commercial programs. With our proprietary shipping systems and 24/7 global dispatch capabilities, our clients can count on seamless, secure, and compliant handling from order to delivery anywhere in the world.

“This isn’t just a new facility, it’s a game-changer for the life sciences industry,” said Jerrell Shelton, CEO of Cryoport. “Our Louvres center empowers biopharma companies, research institutions, and healthcare providers with the tools they need to deliver transformative therapies with unmatched precision and reliability. We’re not just moving materials; we’re moving medicine forward.”

 

A Global Network with Local Impact

Backed by a prestigious grant from the Île-de-France region, the Louvres facility strengthens Cryoport System’s global footprint and also fuels economic growth in the Paris region. Fully integrated with our world-class network, the center upholds the same rigorous quality standards that have made Cryoport Systems a trusted name in life sciences logistics.

 

Join Us for the Grand Celebration!

Mark your calendars for November 20, 2025, when Cryoport Systems will host a grand opening event, uniting local dignitaries, Île-de-France Region leaders, and trailblazers in the European advanced therapies sector. For more information on this exciting event, please visit our event page here.

Category: Supply Chain
Topics: BioServices, Biostorage, Cell Therapy, Europe, Gene Therapy, Global Supply Chain Management

What to read next

Resilience by Design: Lessons from Real-World Disruption
Managing the Cold Chain
10/08/2025

Resilience by Design: Lessons from Real-World Disruption

When it comes to Advanced Therapy Medicinal Products (ATMPs), disruption isn’t an “if,” it’s a “when.” When you’re dealing with unpredictable situations like geopolitical instability, sudden site closures, supply chain bottlenecks, or even weather-related delays, any disruption can potentially jeopardize patient treatments that may be irreplaceable. For sensitive therapies like these with narrow viability windows and strict temperature requirements, even a small deviation in process can have outsized consequences.   In her Beyond Biotech podcast interview with Labiotech, Alison Pritchard, VP of Business Development for EMEA at Cryoport Systems, explained why resilience is one of the most critical (but often overlooked) pillars of ATMP delivery.

Read More

Read More
What’s Slowing the Journey from Therapy to Patient? Inside the Operational Hurdles of ATMPs
Managing the Cold Chain
09/15/2025

What’s Slowing the Journey from Therapy to Patient? Inside the Operational Hurdles of ATMPs

As more advanced therapy medicinal products (ATMPs) move from clinical trials to commercial launch, the industry has reached a critical inflection point. The science is advancing, approvals are accelerating, but patients still face steep barriers to access. In her Beyond Biotech podcast interview with Labiotech, Alison Pritchard, VP of Business Development for EMEA at Cryoport Systems, outlined the operational realities that stand between innovation and patient benefit. These challenges span manufacturing capacity, cold chain infrastructure, site coordination, and regional complexity.

Read More

Read More
Scale Smarter: How Global Supply Chain Centers Amplify CGT Program Growth
Managing the Cold Chain
09/10/2025

Scale Smarter: How Global Supply Chain Centers Amplify CGT Program Growth

Cell and gene therapy (CGT) programs are among the most complex and sensitive operations in the life sciences. From cryopreservation and biostorage to logistics and regulatory compliance, every step in the supply chain can influence product integrity, clinical timelines, and the scalability of the program. For program heads as well as clinical and technical operations teams, the challenge becomes bigger than merely moving materials. It quickly becomes a challenge of scaling efficiently while maintaining compliance and supporting growth across a global network.

Read More

Read More